Zur Kurzanzeige

Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer’s dementia

dc.contributor.authorFrölich, Lutz
dc.contributor.authorPeters, Oliver
dc.contributor.authorLewczuk, Piotr
dc.contributor.authorGruber, Oliver
dc.contributor.authorTeipel, Stefan J.
dc.contributor.authorGertz, Hermann J.
dc.contributor.authorJahn, Holger
dc.contributor.authorJessen, Frank
dc.contributor.authorKurz, Alexander
dc.contributor.authorLuckhaus, Christian
dc.contributor.authorHüll, Michael
dc.contributor.authorPantel, Johannes
dc.contributor.authorReischies, Friedel M.
dc.contributor.authorSchröder, Johannes
dc.contributor.authorWagner, Michael
dc.contributor.authorRienhoff, Otto
dc.contributor.authorWolf, Stefanie
dc.contributor.authorBauer, Chris
dc.contributor.authorSchuchhardt, Johannes
dc.contributor.authorHeuser, Isabella
dc.contributor.authorRüther, Eckart
dc.contributor.authorHenn, Fritz
dc.contributor.authorMaier, Wolfgang
dc.contributor.authorWiltfang, Jens
dc.contributor.authorKornhuber, Johannes
dc.date.accessioned2019-12-17T09:47:37Z
dc.date.available2019-12-17T09:47:37Z
dc.date.issued2017de
dc.relation.ISSN1758-9193de
dc.identifier.urihttp://resolver.sub.uni-goettingen.de/purl?gs-1/16989
dc.description.abstractBackground: Type II diabetes is an important health problem with a complex connection to obesity, leading to a broad range of cardiovascular complications. Insulin therapy often results in weight gain and does not always ensure adequate glycemic control. However, previous studies reported that insulin detemir is an efficient long-acting insulin with a weight sparing effect. The aim of this study was to determine the association of catechol O-methyltransferase (COMT) Val108/158Met and dopamine-beta-hydroxylase (DBH) 1021C/T polymorphisms with the effectiveness of insulin detemir in achieving glucose control and body weight control. Participants and methods: This 52-week observational study included 185 patients with inadequate glycemic control treated with premix insulin analogues, which were replaced with insulin aspart and insulin detemir, and 156 healthy controls. After DNA isolation from blood samples, genotyping of DBH-1021C/T polymorphism (rs1611115) and COMT Val108/158Met polymorphism (rs4680) was performed. Results: Our results confirmed that insulin detemir did not lead to weight gain. The most significant finding was that A carriers (the combined AG and AA genotype) of the COMT Val108/158Met achieved significantly better hemoglobin A1c (HbA1c) values compared to patients carrying GG genotype. No association between DBH-1021C/T genotypes and weight and/or glucose control was detected in diabetes patients or in healthy control subjects. Conclusions: This study showed that the presence of one or two A allele of the COMT Val108/158Met was associated with improved glycemic response, and with a better response to insulin detemir therapy in patients with type II diabetes, separating them as best candidates for detemir therapy.de
dc.language.isoengde
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectBMI; COMT Val108/158Met polymorphism; DBH-1021C/T polymorphism; Hemoglobin A1c (HbA1c); Insulin detemir; Type 2 diabetes mellitusde
dc.subject.ddc573
dc.subject.ddc612
dc.titleIncremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer’s dementiade
dc.typejournalArticlede
dc.identifier.doi10.1186/s13195-017-0301-7
dc.type.versionpublishedVersionde
dc.relation.eISSN1758-9193
dc.bibliographicCitation.volume9de
dc.bibliographicCitation.issue1de
dc.type.subtypejournalArticle
dc.identifier.pmid29225702
dc.bibliographicCitation.articlenumber97de
dc.description.statuspeerReviewedde
dc.bibliographicCitation.journalAlzheimer's Research & Therapyde


Dateien zu dieser Ressource

Thumbnail

Das Dokument erscheint in:

Zur Kurzanzeige

Nutzungslizenz für diese Dokumente:
openAccess